ClinicalTrials.gg
CompletedNCT05448924Updated Jul 8, 2022

Isolated Growth Hormone Deficiency and Amennorrhea

An observational study in Growth Hormone Deficiency, sponsored by Universitas Padjadjaran. Completed at 1 site in Indonesia. Open to female participants. Per ClinicalTrials.gov, last updated 2022-07-08.

Sponsored by Universitas Padjadjaran · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
1
Sex
Female
01

Study summary

This is a case report of a 14-year old female with no menstruation history.

Read the detailed description

This is a case report of a 14-year-old with a chief complaint of inability to menstruate. Lab tests were done.

02

Conditions studied

  • Growth Hormone Deficiency

Keywords

  • ISOLATED GROWTH HORMONE DEFICIENCY
  • AMENORRHEA
03

In context

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

This study's enrollment of 1 is below the median of 70 across 73 observational studies indexed under Dwarfism, Pituitary.

Browse Dwarfism, Pituitary studies →

Lead sponsor

Universitas Padjadjaran is the lead sponsor of 93 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This 14-year old female came to the gynaecology clinic with a chief complaint of amenorrhea

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A single female participant with amenorrhea

Exclusion criteria

Exclusion Criteria:

  • The study only included the above subject
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
1 participant (actual)
Patient registry
No

Interventions

  • Diagnostic testHormone panel tests

    Patient was subjected to a battery of hormone tests, including FSH, LH, estrogen, progesterone and growth hormone

06

What researchers measure

Primary outcomes

  1. Growth hormone levels

    Growth hormone levels assessed by hormone panel

    Time frame: 1 month after testing

07

Study locations

1 site
  • Department of Obstetrics and Gynecology, Universitas Padjadjaran
    Bandung, West Java 40161, Indonesia
08

References and documents

Publications

  • Crottaz B, Uske A, Reymond MJ, Rey F, Temler E, Germond M, Gomez F. Normogonadotropic primary amenorrhea in a growth hormone-deficient woman with ectopic posterior pituitary: gonadotropin pulsatility and follicle-stimulating hormone bioactivity. J Endocrinol Invest. 1996 Jan;19(1):48-53. doi: 10.1007/BF03347858. PubMed 8851692 ↗

Individual participant data

Plan to share: Undecided — Anonymous patient data may be shared with reasonable written request to the authors

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Jan 2022, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2022
First posted
Jul 8, 2022
StartActual
Dec 1, 2021
Primary completionActual
Jan 1, 2022
CompletionActual
Jan 31, 2022
Last update
Jul 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05448924
Lead sponsor
Universitas Padjadjaran
Responsible party
Sponsor
First posted
Jul 8, 2022
Start date
Dec 1, 2021
Primary completion
Jan 1, 2022
Completion
Jan 31, 2022
Last update
Jul 8, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion